

For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm.

Meloxicam Oral Suspension BP (Vet) ARTHROCAM™ 0.5/1.5 mg/ml



Non-Steroidal Anti-Inflammatory Drug for oral use in Dogs & Cats .

COMPOSITION:

Each ml suspension contains:
Meloxicam BP.....0.5 mg/1.5 mg
Flavoured aqueous Base.....q.s.
(Honey Flavour)

INDICATION: For the relief of inflammation and pain in both acute and chronic musculo-skeletal disorders.

DOSE AND ADMINISTRATION:

Dogs:

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Cats:


Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight.

Particular care should be taken with regard to the accuracy of dosing. Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension is given using the measuring syringe provided in the package.

Dosing procedure:

Initial dose: 4 drops/kg body weight
Maintenance dose: 2 drops/kg body weight.

Direction for Administration:



PHARMACODYNAMIC PROPERTIES:

Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams).
ATCvet code: QM01AC06.

PHARMACODYNAMICS:

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

PHARMACOKINETICS:

Absorption: Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution: There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

Metabolism: Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination: Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.

WARNING & PRECAUTION:

Consult a physician in case of accidental ingestion by humans.

As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. The safe use of Meloxicam Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders.

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided.

If additional pain medication is needed after administration of the total daily dose of Meloxicam Oral Suspension, a non-NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. The influence of concomitant drugs that may inhibit metabolism of Meloxicam Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

TARGET SPECIES: Dogs & Cats.

CONTRAINDICATIONS: Do not administer to animals other than those for which it is indicated. Hypersensitivity to any of the Ingredients.

OVERDOSAGE: In case of overdose symptomatic treatment should be initiated.

WITHDRAWAL PERIOD: None.

STORAGE: Store below 25°C in a dry & dark place. Protect from light & moisture.

PRESENTATION: ARTHROCAM 0.5 / 1.5 : 30 ml Amber Pet Bottle with Alu Golden ROPP Cap & 5 ml marked polypropylene Syringe with Adaptor in a Carton along with PI.

SHAKE WELL BEFORE USE.

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD.

Carefully read the accompanying instructions before use.

**VETERINARY,
NOT FOR HUMAN USE.
FOR ANIMAL TREATMENT ONLY.**

Veko®

Manufactured For :

VEKO CARE PVT. LTD.

Room No. 52, 1st Floor, Plot No. E - 48 & E-49, M.I.D.C.,

Ranjangaon, Shirur, Tal. Shirur (Pune - Zone 4) - 412220, India

Customer care : care@vekocare.com TM : Trade Mark of Vekocare

